Evidence map›Paper›PMID 42520140›Full record

Trial reportGut microbes2026

Effect of probiotics on humoral responses to COVID-19 vaccination in older adults: a randomized, placebo-controlled trial (PIRATES-COV study).

Jean-Charles Pasquier, Nils Chaillet, Mélanie Plourde, Guy Boivin, Marie-Ève Hamelin, Hugues Allard-Chamard, Alain Piché, Geneviève Baron, Isabelle Laforest-Lapointe, Mélissa Généreux and 6 more

Registry-linked trialAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Gut microbes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05195151 (Modulation of Immune Responses to COVID-19 Vaccination by an Intervention on the Gut Microbiota), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05195151 nacompletednot on this map

Modulation of Immune Responses to COVID-19 Vaccination by an Intervention on the Gut Microbiota: a Randomized Controlled Trial

TypeinterventionalSponsorUniversité de SherbrookeRan2022 to 2024Enrolled592ConditionsCOVID-19, Vaccine Reaction, ElderlyArmsTaking capsule containing probiotics or placebo
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Jean-Charles PasquierCentre de recherche du Centre hospitalier de l'Université de Montréal, Montreal, Quebec, Canada.ORCID 0009-0007-6182-5902
Nils ChailletUniversité Laval, Quebec City, Quebec, Canada.
Mélanie PlourdeUniversité de Sherbrooke, Sherbrooke, Quebec, Canada.
Guy BoivinUniversité Laval, Quebec City, Quebec, Canada.
Marie-Ève HamelinUniversité Laval, Quebec City, Quebec, Canada.
Hugues Allard-ChamardUniversité de Sherbrooke, Sherbrooke, Quebec, Canada.
Alain PichéUniversité de Sherbrooke, Sherbrooke, Quebec, Canada.
Geneviève BaronUniversité de Sherbrooke, Sherbrooke, Quebec, Canada.
Isabelle Laforest-LapointeUniversité de Sherbrooke, Sherbrooke, Quebec, Canada.
Mélissa GénéreuxUniversité de Sherbrooke, Sherbrooke, Quebec, Canada.
Benoît MâsseCentre hospitalier universitaire Sainte-Justine (CHU Sainte-Justine), Montreal, Quebec, Canada.
Julie RobitailleUniversité Laval, Quebec City, Quebec, Canada.
Jean-François BeaulieuUniversité de Sherbrooke, Sherbrooke, Quebec, Canada.
Tamas FülöpUniversité de Sherbrooke, Sherbrooke, Quebec, Canada.
Sarah BilodeauCentre de recherche du Centre hospitalier de l'Université de Montréal, Montreal, Quebec, Canada.
Sheela RamanathanUniversité de Sherbrooke, Sherbrooke, Quebec, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlthough COVID-19 vaccination has reduced morbidity and mortality, adults aged 65 y old and older are at high risk of complications from COVID-19. The evidence suggests that probiotics may enhance immune responses when co-administered with influenza vaccination. However, few studies have evaluated the potential benefit of probiotic supplementation in this context in this high-risk population. MATERIAL: This study was a randomized controlled trial recruiting adults between 65 and 89 y of age living in Quebec, Canada, who received an mRNA booster (Pfizer-BioNTech or Moderna). Probiotic supplementation (

results592 adults were enrolled. At 6 months post-vaccination, anti-S1-RBD antibodies were comparable between groups, and the percentage of participants with undetectable antibody response in the placebo and probiotic groups (1.2% vs 1.6%) was comparable. Anti-

conclusionProbiotic supplementation administered around COVID-19 vaccination did not change the proportion of seronegative participants for anti-S1-RBD antibodies at 6 months. However, in the probiotic group, anti- TRIAL REGISTRATION NUMBER: #NCT05195151.

Indexed as

COVID-19COVID-19 VaccinesImmunity, HumoralProbioticsAgedAged, 80 and overAntibodies, ViralFemaleHumansLacticaseibacillus paracaseiLacticaseibacillus rhamnosusMaleQuebecSARS-CoV-2VaccinationAntibodies, ViralCOVID-19 Vaccinesagingclinical trialCOVID-19immunityprobioticvaccination

Identifiers

PMID42520140
PMCPMC13418469

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.